Top Medical Searches

Sandoz says new clinical data support two biosimilars

ZURICH (Reuters) – Novartis’ generics division, Sandoz, said new immunology data from four clinical studies supported its proposed biosimilars adalimumab for treating psoriasis and cancer drug rituximab.

 Read more…

Be Sociable, Share!
November 14th, 2017 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us